MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5114/aic.2018.76406

Медицинская библиотека · Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2018

Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry.

Orlik Bartłomiej, Milewski Krzysztof, Derbisz Kamil, Jelonek Michał, Chrząszcz Patrycja, Beil Sonia, Młodziankowski Adam, Picheta Wojciech, Buszman Piotr P, Buszman Paweł E

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Most clinical trials related to bioresorbable vascular scaffold (BVS) technology are limited to a highly selected patient population.

AIM: To evaluate early and long-term clinical outcomes of the Absorb everolimus-eluting BVS compared to the everolimus-eluting metallic XIENCE V stent in routine clinical practice.

MATERIAL AND

METHODS

This is a multicenter, retrospective propensity score-matched comparative study, comprising 76 patients treated with a bare metal stents (BMS) and 501 with a XIENCE stent. Patients included in the study had stable and unstable angina and both types of myocardial infarction (STEMI and NSTEMI) as an indication for intervention and at least one significant de novo lesion in native coronary arteries. The primary endpoint was major adverse cardiovascular event (MACE), defined as death, myocardial infarction (MI), or target vessel revascularization (TVR).

RESULTS

Median follow-up was 400 days in both groups. After propensity score matching for patient baseline characteristics, only higher rate of predilatation, predominantly treated left anterior descending artery (LAD) and lower number of used stents in the BVS group remained statistically significant. After adjustment there was no difference in type of treated lesions. The MACE rate did not differ between BVS and drug-eluting stents (DES) groups (7.2% vs. 11.15%, respectively; p = 0.17). The TVR was 2.9% in both groups. Except in the periprocedural period, there were no deaths or MI in the BVS group. There was no stent thrombosis in either studied group.

CONCLUSIONS

In routine clinical practice throughout long-term follow-up, clinical outcomes of patients who successfully received the Absorb BVS did not differ from those of patients who received the Xience stent. Longer follow-up data are required to determine whether these findings will persist beyond one year.

Для цитирования: Orlik Bartłomiej, Milewski Krzysztof, Derbisz Kamil, Jelonek Michał, Chrząszcz Patrycja, Beil Sonia, Młodziankowski Adam, Picheta Wojciech, Buszman Piotr P, Buszman Paweł E. Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry.. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology. 2018. DOI: 10.5114/aic.2018.76406.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.